O	0	4	Long
O	4	5	-
O	5	9	term
O	10	17	cardiac
O	18	24	follow
O	24	25	-
O	25	27	up
O	28	30	in
O	31	38	relapse
O	38	39	-
O	39	43	free
O	44	52	patients
O	53	58	after
O	59	62	six
O	63	70	courses
O	71	73	of
B-intervention	74	86	fluorouracil
I-intervention	86	87	,
I-intervention	88	98	epirubicin
I-intervention	98	99	,
I-intervention	100	103	and
I-intervention	104	120	cyclophosphamide
I-intervention	120	121	,
I-intervention	122	126	with
I-intervention	127	133	either
I-intervention	134	136	50
I-intervention	137	139	or
I-intervention	140	143	100
I-intervention	144	146	mg
I-intervention	147	149	of
I-intervention	150	160	epirubicin
O	160	161	,
O	162	164	as
O	165	173	adjuvant
O	174	181	therapy
O	182	185	for
B-eligibility	186	190	node
I-eligibility	190	191	-
I-eligibility	191	199	positive
I-eligibility	200	206	breast
I-eligibility	207	213	cancer
O	213	214	:
B-location	215	221	French
O	222	230	adjuvant
O	231	236	study
O	237	242	group
O	242	243	.

O	244	251	PURPOSE
O	252	254	To
O	255	263	evaluate
O	264	268	long
O	268	269	-
O	269	273	term
O	274	281	cardiac
O	282	290	function
O	291	293	in
O	294	302	patients
O	303	310	without
O	311	318	disease
O	319	322	who
O	323	326	had
O	327	335	received
O	336	339	six
O	340	346	cycles
O	347	349	of
O	350	362	fluorouracil
O	363	366	500
O	367	369	mg
O	369	370	/
O	370	371	m
O	371	372	(
O	372	373	2
O	373	374	)
O	374	375	,
O	376	386	epirubicin
O	387	389	50
O	390	392	mg
O	392	393	/
O	393	394	m
O	394	395	(
O	395	396	2
O	396	397	)
O	397	398	,
O	399	402	and
O	403	419	cyclophosphamide
O	420	423	500
O	424	426	mg
O	426	427	/
O	427	428	m
O	428	429	(
O	429	430	2
O	430	431	)
O	432	433	(
O	433	436	FEC
O	437	439	50
O	439	440	)
O	441	443	or
O	444	447	the
O	448	452	same
O	453	460	regimen
O	461	465	with
O	466	476	epirubicin
O	477	480	100
O	481	483	mg
O	483	484	/
O	484	485	m
O	485	486	(
O	486	487	2
O	487	488	)
O	489	490	(
O	490	493	FEC
O	494	497	100
O	497	498	)
O	499	501	as
O	502	510	adjuvant
O	511	523	chemotherapy
O	524	527	for
O	528	532	node
O	532	533	-
O	533	541	positive
O	542	548	breast
O	549	555	cancer
O	556	558	in
O	559	562	the
O	563	569	French
O	570	578	Adjuvant
O	579	584	Study
O	585	590	Group
O	590	591	-
O	591	593	05
O	594	599	trial
O	599	600	.

O	601	609	PATIENTS
O	610	613	AND
O	614	621	METHODS
B-total-participants	622	625	One
I-total-participants	626	633	hundred
I-total-participants	634	639	fifty
I-total-participants	640	648	patients
O	649	650	(
O	650	653	FEC
O	654	656	50
O	656	657	,
O	658	659	n
O	660	661	=
B-intervention-participants	662	664	65
O	664	665	;
B-control	666	669	FEC
I-control	670	673	100
O	673	674	,
O	675	676	n
O	677	678	=
B-control-participants	679	681	85
O	681	682	)
O	683	686	who
O	687	691	were
O	692	699	without
O	700	707	disease
O	708	711	and
O	712	715	who
O	716	720	gave
O	721	726	their
O	727	735	informed
O	736	743	consent
O	744	748	were
O	749	757	enrolled
O	758	761	for
O	762	766	long
O	766	767	-
O	767	771	term
O	772	779	cardiac
O	780	790	assessment
O	790	791	.

O	792	795	The
O	796	806	assessment
O	807	815	included
O	816	823	cardiac
O	824	830	events
O	831	840	occurring
O	841	846	after
O	847	850	the
O	851	854	end
O	855	857	of
O	858	870	chemotherapy
O	870	871	,
O	872	877	vital
O	878	883	signs
O	883	884	,
O	885	896	concomitant
O	897	904	disease
O	904	905	,
O	906	909	ECG
O	909	910	,
O	911	919	isotopic
O	920	924	left
O	925	936	ventricular
O	937	945	ejection
O	946	954	fraction
O	955	956	(
O	956	960	LVEF
O	960	961	)
O	961	962	,
O	963	966	and
O	967	978	echographic
O	979	989	parameters
O	989	990	.

O	991	999	Abnormal
O	1000	1005	files
O	1006	1010	were
O	1011	1018	blindly
O	1019	1027	reviewed
O	1028	1030	by
O	1031	1044	cardiologists
O	1045	1048	and
O	1049	1060	oncologists
O	1060	1061	.

O	1062	1069	Results
O	1070	1073	The
O	1074	1080	median
O	1081	1087	follow
O	1087	1088	-
O	1088	1090	up
O	1091	1095	time
O	1096	1099	was
O	1100	1103	102
O	1104	1110	months
O	1110	1111	.

O	1112	1117	After
O	1118	1121	FEC
O	1122	1125	100
O	1125	1126	,
B-outcome	1127	1131	LVEF
I-outcome	1132	1135	was
I-outcome	1136	1140	less
I-outcome	1141	1145	than
I-outcome	1146	1148	50
I-outcome	1148	1149	%
O	1150	1152	in
B-iv-bin-abs	1153	1157	five
O	1158	1166	patients
O	1167	1168	(
O	1168	1181	radioisotopic
O	1182	1188	method
O	1188	1189	)
O	1189	1190	,
O	1191	1194	and
B-iv-bin-abs	1195	1198	two
O	1199	1207	patients
O	1208	1219	experienced
B-outcome	1220	1230	congestive
I-outcome	1231	1236	heart
I-outcome	1237	1244	failure
I-outcome	1245	1246	(
I-outcome	1246	1249	CHF
I-outcome	1249	1250	)
O	1251	1255	that
O	1256	1259	was
O	1260	1268	possibly
O	1269	1276	related
O	1277	1279	to
O	1280	1289	treatment
O	1289	1290	.

B-outcome	1291	1303	Asymptomatic
I-outcome	1304	1308	left
I-outcome	1309	1320	ventricular
I-outcome	1321	1332	dysfunction
I-outcome	1333	1334	(
I-outcome	1334	1337	LVD
I-outcome	1337	1338	)
O	1339	1342	was
O	1343	1354	experienced
O	1355	1357	in
B-iv-bin-abs	1358	1360	18
O	1361	1369	patients
O	1370	1375	after
O	1376	1379	FEC
O	1380	1383	100
O	1384	1387	and
O	1388	1390	in
B-cv-bin-abs	1391	1394	one
O	1395	1402	patient
O	1403	1408	after
O	1409	1412	FEC
O	1413	1415	50
O	1415	1416	.

O	1417	1419	In
O	1420	1425	these
O	1426	1434	patients
O	1434	1435	,
B-outcome	1436	1445	treatment
I-outcome	1446	1455	causality
O	1456	1459	was
O	1460	1468	probable
O	1469	1471	in
O	1472	1477	eight
O	1478	1486	patients
O	1486	1487	.

O	1488	1491	Two
O	1492	1502	additional
O	1503	1508	years
O	1509	1514	after
O	1515	1519	this
O	1520	1530	assessment
O	1530	1531	,
O	1532	1535	all
O	1536	1538	18
O	1539	1547	patients
O	1548	1552	were
O	1553	1558	still
O	1559	1571	asymptomatic
O	1571	1572	.

O	1573	1583	CONCLUSION
O	1584	1589	After
O	1590	1594	more
O	1595	1599	than
O	1600	1601	8
O	1602	1607	years
O	1608	1610	of
O	1611	1617	follow
O	1617	1618	-
O	1618	1620	up
O	1620	1621	,
O	1622	1625	the
O	1626	1633	cardiac
O	1634	1642	toxicity
O	1643	1651	observed
O	1652	1657	after
O	1658	1666	adjuvant
O	1667	1676	treatment
O	1677	1681	with
O	1682	1685	FEC
O	1686	1689	100
O	1690	1699	comprised
O	1700	1703	two
O	1704	1709	cases
O	1710	1712	of
O	1713	1717	well
O	1717	1718	-
O	1718	1728	controlled
O	1729	1732	CHF
O	1733	1736	and
O	1737	1739	18
O	1740	1745	cases
O	1746	1748	of
O	1749	1761	asymptomatic
O	1762	1765	LVD
O	1765	1766	.

O	1767	1769	In
O	1770	1773	the
O	1774	1782	majority
O	1783	1785	of
O	1786	1791	women
O	1792	1796	with
O	1797	1804	primary
O	1805	1811	breast
O	1812	1818	cancer
O	1818	1819	,
O	1820	1823	the
O	1824	1832	benefits
O	1833	1835	of
O	1836	1845	treatment
O	1846	1850	with
O	1851	1854	FEC
O	1855	1858	100
O	1859	1861	in
O	1862	1867	terms
O	1868	1870	of
O	1871	1878	disease
O	1878	1879	-
O	1879	1883	free
O	1884	1887	and
O	1888	1895	overall
O	1896	1904	survival
O	1905	1913	outweigh
O	1914	1917	the
O	1918	1923	risks
O	1923	1924	,
O	1925	1928	and
O	1929	1936	cardiac
O	1937	1941	risk
O	1942	1949	factors
O	1950	1956	should
O	1957	1959	be
O	1960	1969	carefully
O	1970	1979	evaluated
O	1980	1982	in
O	1983	1990	patient
O	1991	2000	selection
O	2000	2001	.
